Shire And Mylan Start New Era In Japan: Emerging Markets Roundup (Part 6)
This article was originally published in PharmAsia News
Executive Summary
Shire’s ADHD portfolio was a boost in Japan, but also carries high risk of generic cannibalization in the near future. Mylan and Pfizer ready to launch first generic tacrolimus in Japan next month.
You may also be interested in...
FDA’s Autor Moves To Mylan: Company’s Gain May Also Be Company’s Loss
While Mylan wants Autor to help push quality improvement efforts around the world, her departure from FDA may affect implementation of similar plans at the agency.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.